TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1559542

Group type: EXPERIMENTAL
Intervention: rhGM-CSF (8 micrograms kg‐1) via intravenous (i.v.) bolus injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rhGM-CSF (8 micrograms kg‐1) via subcutaneous (s.c.) bolus injection
Number of subjects: 0
Study: 3888863

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Naproxen 1000 mg daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pre-trial medication
Number of subjects: 24
Study: 31372796

Group type: EXPERIMENTAL
Intervention: Adaptive online learning module
Number of subjects: 114

Group type: COMPARATOR
Intervention: High interactivity
Number of subjects: 114

Group type: COMPARATOR
Intervention: Low interactivity
Number of subjects: 114
Study: 29174115

Group type: EXPERIMENTAL
Intervention: 20mg ponesimod
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: 40mg ponesimod
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Predicted 10mg ponesimod
Number of subjects: 326
Study: 26605752

Group type: EXPERIMENTAL
Intervention: Adapted guide prior to visit plus decision aid during visit (arm 3)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Existing medication guide prior to clinic visit (arm 1)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Adapted guide prior to visit (arm 2)
Number of subjects: 166
Study: 24846909

Group type: EXPERIMENTAL
Intervention: Text4baby plus usual care
Number of subjects: 943

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 943
Study: 22158529

Group type: EXPERIMENTAL
Intervention: Nebulised bronchodilator therapy driven by oxygen
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nebulised bronchodilator therapy driven by air
Number of subjects: 18
Study: 19651523

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel
Number of subjects: 0
Study: 18773451

Group type: EXPERIMENTAL
Intervention: Mean ovarian volume (MOV) threshold at 6.4 cm³
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Maximum ovarian volume (MaxOV) threshold at 7.9 cm³
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Mean follicle number (MFN) threshold at 10
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Maximum follicle number (MaxFN) threshold at 12
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Ovarian volume in PCOS patients
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Follicle number in PCOS patients
Number of subjects: 432

Group type: COMPARATOR
Intervention: Ovarian volume in controls
Number of subjects: 432

Group type: COMPARATOR
Intervention: Follicle number in controls
Number of subjects: 432
Study: 15741029

Group type: EXPERIMENTAL
Intervention: Intra‐oral distraction devices
Number of subjects: 54

Group type: COMPARATOR
Intervention: Extra‐oral distraction devices
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study: 11772601

Group type: EXPERIMENTAL
Intervention: Laser in situ keratomileusis (LASIK) for low to moderate myopia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser in situ keratomileusis (LASIK) for moderate to high myopia (>6.0 D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser in situ keratomileusis (LASIK) for mild to moderate degrees of astigmatism (<2.0 D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser in situ keratomileusis (LASIK)
Number of subjects: 0
Study: 10332685

Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 22

Group type: COMPARATOR
Intervention: Human insulin (injected immediately before the meal)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Human insulin (injected 30 min before the meal)
Number of subjects: 22
Study: 8951251

Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (HFJV)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 73
Study: 2019357

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Mylanta
Number of subjects: 57
Study: 31492152

Group type: COMPARATOR
Intervention: TAC monotherapy (n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TAC combined with MMF (n = 20)
Number of subjects: 40
Study: 26796076

Group type: EXPERIMENTAL
Intervention: Hypoxic exercise
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normoxic exercise
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups (normoxic and hypoxic)
Number of subjects: 14
Study: 24901809

Group type: EXPERIMENTAL
Intervention: 4.5 mg · kg⁻¹ of caffeine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (0 mg of caffeine per kg of body weight)
Number of subjects: 12
Study: 22669421

Group type: EXPERIMENTAL
Intervention: Autologous fascial sling (SISTEr trial)
Number of subjects: 1233

Group type: EXPERIMENTAL
Intervention: Retropubic mid-urethral sling (TOMUS trial)
Number of subjects: 1233
Study: 20938438

Group type: EXPERIMENTAL
Intervention: Lupin-enriched foods
Number of subjects: 131
Study: 21602751

Group type: COMPARATOR
Intervention: 1% isoflurane (Group I, N=20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol 6 mg kg h(‐1) (Group P, N=20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Group I and Group P)
Number of subjects: 40
Study: 17915971

Group type: EXPERIMENTAL
Intervention: Diurnal mood variation (DMV)
Number of subjects: 3744

Group type: EXPERIMENTAL
Intervention: DMV
Number of subjects: 3744
Study: 16142862

Group type: EXPERIMENTAL
Intervention: Intraarticular (IA) triamcinolone hexacetonide injection
Number of subjects: 69

Group type: COMPARATOR
Intervention: Intramuscular (IM) triamcinolone acetonide mini-pulse therapy
Number of subjects: 69
Study: 12096682

Group type: EXPERIMENTAL
Intervention: Signal/noise ratio +15
Number of subjects: 0

Group type: COMPARATOR
Intervention: Signal/noise ratio (not specified)
Number of subjects: 0
Study: 10535229

Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program (ISFP)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Preparing for the Drug‐Free Years program (PDFY)
Number of subjects: 329
Study: 7572244

Group type: EXPERIMENTAL
Intervention: Self-control therapy program
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 25
Study: 2338632

Group type: EXPERIMENTAL
Intervention: SR-verapamil fasting (1 X 240 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SR-verapamil with food (1 X 240 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional formulation of verapamil fasting (3 X 80 mg)
Number of subjects: 12
Study: 7448345

Group type: EXPERIMENTAL
Intervention: Quinidine formulation 1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Quinidine formulation 2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Quinidine formulation 3
Number of subjects: 12
Study: 30423463

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (15 x 300 mg capsules per day for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison between Omega-3 and Placebo
Number of subjects: 0
Study: 29127432

Group type: EXPERIMENTAL
Intervention: DSAEK with donor cornea preservation time (PT) of 0 to 7 days (0-7d PT)
Number of subjects: 769

Group type: COMPARATOR
Intervention: DSAEK with donor cornea preservation time (PT) of 8 to 14 days (8-14d PT)
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Longer PT analyzed as a continuous variable
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Extension study results at 4 years for 0-7d PT
Number of subjects: 769

Group type: COMPARATOR
Intervention: Extension study results at 4 years for 8-14d PT
Number of subjects: 769
Study: 26468632

Group type: EXPERIMENTAL
Intervention: Earlier appointment to outpatient cardiac rehabilitation (CR) at HFH (8 days)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard routine appointment to outpatient cardiac rehabilitation (CR) at Mayo Clinic (10 days after discharge)
Number of subjects: 148
Study: 23493643

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (234 mg on day 1, 156 mg on day 8, then once-monthly flexible dosing)
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable (RLAI) (25-50 mg biweekly, with oral risperidone supplementation on days 1-28)
Number of subjects: 747
Study: 21627523

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Polysulfated glycosaminoglycan treatment (PSGAGT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham ESWT (placebo)
Number of subjects: 24
Study: 19862981

Group type: EXPERIMENTAL
Intervention: Warfarin with target INR of 1.50 to 1.99 (Group A)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Warfarin with target INR of 2.00 to 2.50 (Group B)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Warfarin with target INR of 2.51 to 3.00 (Group C)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Warfarin with target INR of 1.50 to 2.50 (Group A and B)
Number of subjects: 180
Study: 16681849

Group type: COMPARATOR
Intervention: Lesbian women
Number of subjects: 1605

Group type: COMPARATOR
Intervention: Bisexual women
Number of subjects: 1605

Group type: COMPARATOR
Intervention: Gay men
Number of subjects: 1605

Group type: COMPARATOR
Intervention: Bisexual men
Number of subjects: 1605

Group type: COMPARATOR
Intervention: Lesbian, gay, and bisexual classified people
Number of subjects: 1605
Study: 15169803

Group type: EXPERIMENTAL
Intervention: TAP (doxorubicin 45 mg/m(2), cisplatin 50 mg/m(2), paclitaxel 160 mg/m(2) with filgrastim)
Number of subjects: 273

Group type: COMPARATOR
Intervention: AP (doxorubicin 60 mg/m(2), cisplatin 50 mg/m(2))
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: TAP
Number of subjects: 273

Group type: COMPARATOR
Intervention: AP
Number of subjects: 273
Study: 11419831

Group type: EXPERIMENTAL
Intervention: Covered stents
Number of subjects: 62

Group type: COMPARATOR
Intervention: Uncovered stents
Number of subjects: 62
Study: 9426847

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8489566

Group type: EXPERIMENTAL
Intervention: Immediate release bezafibrate 300 mg dragee (A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sustained release bezafibrate 400 mg dragee (B)
Number of subjects: 0
Study: 3318368

Group type: EXPERIMENTAL
Intervention: Mexiletine (200 to 400 mg every 8 hours)
Number of subjects: 491

Group type: COMPARATOR
Intervention: Quinidine (200 to 400 mg every 6 hours)
Number of subjects: 491

Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 491
Study: 28426897

Group type: EXPERIMENTAL
Intervention: Aware condition
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Count duration of 15 seconds
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Count duration of 30 seconds
Number of subjects: 82

Group type: COMPARATOR
Intervention: Unaware condition
Number of subjects: 82
Study: 27162173

Group type: COMPARATOR
Intervention: ASP015K (peficitinib) 3 mg to 300 mg single dose
Number of subjects: 20

Group type: COMPARATOR
Intervention: ASP015K (30 mg) multiple doses
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24998109

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (1g administered 30 min prior to operation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Number of subjects: 60
Study: 22649162

Group type: EXPERIMENTAL
Intervention: Cognitive Sensory Motor Training Therapy (Perfetti's method)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional occupational therapy
Number of subjects: 40
Study: 20854237

Group type: EXPERIMENTAL
Intervention: Systematic asthma care involving a register-recall system, postcard prompts for review, and education for general practitioners and staff.
Number of subjects: 565

Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 565
Study: 19029500

Group type: EXPERIMENTAL
Intervention: Extended-care programs (telephone and face-to-face)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Education control group (26 biweekly newsletters)
Number of subjects: 234
Study: 16125761

Group type: EXPERIMENTAL
Intervention: Outreach and counseling intervention
Number of subjects: 348

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 348
Study: 12098612

Group type: EXPERIMENTAL
Intervention: Pain communication intervention
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: PTSD diagnosis (53.8% of participants)
Number of subjects: 145
Study: 10189646

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine buffered 9:1 with 8.4% sodium bicarbonate
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine diluted 1:9 with 0.9% bacteriostatic saline solution
Number of subjects: 30
Study: 7780131

Group type: EXPERIMENTAL
Intervention: rBPI23 (1 mg/kg)
Number of subjects: 8
Study: 2185335

Group type: EXPERIMENTAL
Intervention: Recall system and patient education material by mail
Number of subjects: 178
Study: 376786

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30406937

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 3528

Group type: EXPERIMENTAL
Intervention: Non-vitamin K oral anticoagulants (NOACs)
Number of subjects: 3528
Study: 31392719

Group type: EXPERIMENTAL
Intervention: Educational programme
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 70
Study: 29472255

Group type: EXPERIMENTAL
Intervention: Emotional stimulus group (EG) - watched an emotionally stimulating video prior to the BLS course
Number of subjects: 271

Group type: COMPARATOR
Intervention: Assessment group (AG) - practical assessment of the BLS algorithm announced and tested
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Both groups (EG and AG)
Number of subjects: 271
Study: 27797697

Group type: EXPERIMENTAL
Intervention: Alcohol media literacy program (10 lessons)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 165

Group type: COMPARATOR
Intervention: Both groups (intervention and control)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Alcohol media literacy program
Number of subjects: 165
Study: 25146009

Group type: EXPERIMENTAL
Intervention: Combination of 3% mepivacaine plus 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Combination of 2% lidocaine with 1:100,000 epinephrine plus 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 100
Study: 22545190

Group type: EXPERIMENTAL
Intervention: SURG+AMOX+MET+TET
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: SURG
Number of subjects: 229

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 229

Group type: COMPARATOR
Intervention: SURG+systemic amoxicillin+systemic metronidazole
Number of subjects: 229

Group type: COMPARATOR
Intervention: SURG+local tetracycline
Number of subjects: 229

Group type: COMPARATOR
Intervention: AMOX+MET+TET
Number of subjects: 229

Group type: COMPARATOR
Intervention: AMOX+MET
Number of subjects: 229

Group type: COMPARATOR
Intervention: TET
Number of subjects: 229
Study: 20008028

Group type: EXPERIMENTAL
Intervention: Reasoning intervention group
Number of subjects: 1534

Group type: EXPERIMENTAL
Intervention: Speed of processing intervention group
Number of subjects: 1534

Group type: COMPARATOR
Intervention: Memory intervention group
Number of subjects: 1534

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 1534
Study: 18341676

Group type: EXPERIMENTAL
Intervention: Aerochamber Plus spacer (AP)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Synchro‐Breathe (SB) device
Number of subjects: 17

Group type: COMPARATOR
Intervention: pMDI Evohaler (EH)
Number of subjects: 17
Study: 15981555

Group type: EXPERIMENTAL
Intervention: Nebivolol (target dose 5 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12706495

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (INO) at 20 ppm
Number of subjects: 22
Study: 10606909

Group type: EXPERIMENTAL
Intervention: Intraportal infusion of lymphokine‐activated killer (LAK) cells combined with recombinant interleukin 2 (rIL‐2)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (tumour resection and IORT)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Treatment group (resection, IORT and LAK cells with rIL-2)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 29
Study: 8847783

Group type: EXPERIMENTAL
Intervention: Amrinon (AM) 1 microgram.kg-1 followed by AM 5 micrograms.kg-1.min-1
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PG) 0.02 micrograms.kg-1.min-1
Number of subjects: 39

Group type: COMPARATOR
Intervention: Dopamine (DOA) 3 micrograms.kg-1.min-1 (Control)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: AM and PG groups
Number of subjects: 39
Study: 1734247

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (1 g per day for 3 days, followed by oral prednisone 1 mg/kg/day for 11 days)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Oral prednisone (1 mg/kg/day for 14 days)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Placebo (oral for 14 days)
Number of subjects: 457
Study: 6432198

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31663905

Group type: EXPERIMENTAL
Intervention: Diagnostic nomogram based on age, CA19.9, and 6 radiological features.
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 587
Study: 30245282

Group type: EXPERIMENTAL
Intervention: Puerarin 400mg
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control (no puerarin)
Number of subjects: 119
Study: 26786575

Group type: EXPERIMENTAL
Intervention: Intensive therapy group (74% experienced serious hypoglycemia)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard treatment group (21% experienced serious hypoglycemia)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard treatment group
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Intensive therapy group
Number of subjects: 197
Study: 25480613

Group type: EXPERIMENTAL
Intervention: Snare cauterization
Number of subjects: 62

Group type: COMPARATOR
Intervention: Clip closure
Number of subjects: 62
Study: 22629322

Group type: EXPERIMENTAL
Intervention: Adjustment for a strong prognostic factor (PF) with relative risk = 5
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Adjustment for a weak prognostic factor (PF) with relative risk = 2
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Including 1000 patients/arm
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Including 2000 patients/arm
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Logistic regression models with adjustment for PF
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Logistic regression models without adjustment for PF
Number of subjects: 125
Study: 20236094

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg i.v.
Number of subjects: 113

Group type: COMPARATOR
Intervention: Diphenhydramine 25 mg i.v.
Number of subjects: 113
Study: 18519309

Group type: EXPERIMENTAL
Intervention: Internal fixation with a Herbert screw
Number of subjects: 83

Group type: COMPARATOR
Intervention: Nonoperative treatment with a cast
Number of subjects: 83
Study: 16042226

Group type: EXPERIMENTAL
Intervention: IVIG (1 g/kg body weight monthly for 27 months)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo (albumin 0.1% monthly for 27 months)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study: 12457125

Group type: EXPERIMENTAL
Intervention: La Léchère mineral water
Number of subjects: 10

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 10
Study: 10609979

Group type: EXPERIMENTAL
Intervention: Alcohol intoxication
Number of subjects: 0
Study: 8949805

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1 (2xED95)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg kg‐1 (3xED95)
Number of subjects: 100
Study: 1918655

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 120
Study: 6437699

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29157034

Group type: EXPERIMENTAL
Intervention: Pregabalin plus IV ibuprofen (150 mg pregabalin and 400 mg IV ibuprofen)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Pregabalin (150 mg)
Number of subjects: 58
Study: 29427823

Group type: EXPERIMENTAL
Intervention: Standardized strategy
Number of subjects: 676

Group type: COMPARATOR
Intervention: Open strategy
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Standardized strategy - first step tests
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Standardized strategy - second step tests
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Standardized group vs Open group for HLA B27 and ACE
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Free investigations or guided tests
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Third intention tests
Number of subjects: 676
Study: 27213500

Group type: EXPERIMENTAL
Intervention: Supramaximal interval training (10 cycles of 10-second work at 140% peak aerobic power with 5-second recovery, repeated 6 times)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Continuous training (predominantly moderate intensity below lactate threshold)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (Supramaximal and Continuous)
Number of subjects: 16